Efficacy and safety of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies
Rasko, J., Walters, M., Kwiatkowski, J., Hongeng, S., Porter, J., Sauer, M., Thrasher, A., Thuret, I., Schiller, G., Elliot, H., Deary, B., Chen, Y., Tao, G., Asmal, M., Locatelli, F., Thompson, A.Volume:
21
Journal:
Cytotherapy
DOI:
10.1016/j.jcyt.2019.03.578
Date:
May, 2019
File:
PDF, 60 KB
2019